{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:48:44Z","timestamp":1782780524955,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40264-021-01067-x","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T02:02:40Z","timestamp":1622080960000},"page":"711-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8858-9435","authenticated-orcid":false,"given":"Kunihiro","family":"Yamaoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4330-5782","authenticated-orcid":false,"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhito","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-2603","authenticated-orcid":false,"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1111-8218","authenticated-orcid":false,"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"issue":"8","key":"1067_CR1","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3390\/cells8080898","volume":"8","author":"A Alunno","year":"2019","unstructured":"Alunno A, Padjen I, Fanouriakis A, Boumpas DT. Pathogenic and therapeutic relevance of JAK\/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells. 2019;8(8):898. https:\/\/doi.org\/10.3390\/cells8080898.","journal-title":"Cells"},{"issue":"5\u20136","key":"1067_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1759720X18776224","volume":"10","author":"CJ Malemud","year":"2018","unstructured":"Malemud CJ. The role of the JAK\/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10(5\u20136):117\u201327. https:\/\/doi.org\/10.1177\/1759720X18776224.","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"10086","key":"1067_CR3","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. 2017;389(10086):2328\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(17)31472-1.","journal-title":"Lancet"},{"key":"1067_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23. https:\/\/doi.org\/10.1186\/s41927-018-0031-x.","journal-title":"BMC Rheumatol."},{"issue":"10139","key":"1067_CR5","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(18)31115-2.","journal-title":"Lancet"},{"issue":"11","key":"1067_CR6","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheum. 2019;71(11):1788\u2013800. https:\/\/doi.org\/10.1002\/art.41032.","journal-title":"Arthritis Rheum."},{"issue":"10139","key":"1067_CR7","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(18)31116-4.","journal-title":"Lancet"},{"key":"1067_CR8","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(19)30419-2.","journal-title":"Lancet"},{"key":"1067_CR9","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed MF, Chen S, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-na\u00efve patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a randomized, double-blind, active-comparator, multi-center, multi-country trial. Arthritis Rheum. 2020;72:1607\u201320. https:\/\/doi.org\/10.1002\/art.41384.","journal-title":"Arthritis Rheum."},{"issue":"5","key":"1067_CR10","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/14397595.2020.1782049","volume":"30","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30(5):779\u201387. https:\/\/doi.org\/10.1080\/14397595.2020.1782049.","journal-title":"Mod Rheumatol."},{"issue":"S2","key":"1067_CR11","first-page":"1408","volume":"77","author":"T Mimori","year":"2018","unstructured":"Mimori T, Harigai M, Atsumi T, Kuwana M, Takei S, Tamura N, et al. AB0495 post-marketing surveillance of tofacitinib in Japanese patients with rheumatoid arthritis: an interim report of safety data. Ann Rheum Dis. 2018;77(S2):1408.","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"1067_CR12","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1136\/annrheumdis-2019-215163","volume":"78","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Takeuchi T, Tanaka S, Kawakami A, Iwasaki M, Song YW, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019;78(10):1320\u201332. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215163.","journal-title":"Ann Rheum Dis."},{"key":"1067_CR13","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","volume":"66","author":"KL Winthrop","year":"2014","unstructured":"Winthrop KL, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675\u201384. https:\/\/doi.org\/10.1002\/art.38745.","journal-title":"Arthritis Rheumatol."},{"key":"1067_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/14397595.2019.1583711","volume":"30","author":"M Harigai","year":"2020","unstructured":"Harigai M, Takeuchi T, Smolen JS, Winthrop KL, Nishikawa A, Rooney TP, et al. Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: an integrated analysis of Phases 2 and 3 trials. Mod Rheumatol. 2020;30:36\u201343. https:\/\/doi.org\/10.1080\/14397595.2019.1583711.","journal-title":"Mod Rheumatol."},{"key":"1067_CR15","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69:1960\u20138. https:\/\/doi.org\/10.1002\/art.40189.","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"1067_CR16","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","volume":"59","author":"H Kameda","year":"2020","unstructured":"Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y, et al. Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study. Rheumatology (Oxford). 2020;59(11):3303\u201313. https:\/\/doi.org\/10.1093\/rheumatology\/keaa084.","journal-title":"Rheumatology (Oxford)"},{"key":"1067_CR17","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/art.39801","volume":"68","author":"JM Kremer","year":"2016","unstructured":"Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol. 2016;68:2867\u201377. https:\/\/doi.org\/10.1002\/art.39801.","journal-title":"Arthritis Rheumatol."},{"key":"1067_CR18","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/art.39808","volume":"68","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016;68:2857\u201366. https:\/\/doi.org\/10.1002\/art.39808.","journal-title":"Arthritis Rheumatol."},{"key":"1067_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/cpdd.462","volume":"8","author":"MF Mohamed","year":"2019","unstructured":"Mohamed MF, Zeng J, Marroum PJ, Song IH, Othman AA. Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials. Clin Pharmacol Drug Dev. 2019;8:208\u201316. https:\/\/doi.org\/10.1002\/cpdd.462.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1067_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","volume":"29","author":"H Kameda","year":"2019","unstructured":"Kameda H, Fujii T, Nakajima A, Koike R, Sagawa A, Kanbe K, et al. Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol. 2019;29:31\u201340. https:\/\/doi.org\/10.1080\/14397595.2018.1472358.","journal-title":"Mod Rheumatol."},{"key":"1067_CR21","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3899\/jrheum.140778","volume":"42","author":"H Yamazaki","year":"2015","unstructured":"Yamazaki H, Sakai R, Koike R, Miyazaki Y, Tanaka M, Nanki T, et al. Assessment of risks of pulmonary infection during 12 months following immunosuppressive treatment for active connective tissue diseases: a large-scale prospective cohort study. J Rheumatol. 2015;42:614\u201322. https:\/\/doi.org\/10.3899\/jrheum.140778.","journal-title":"J Rheumatol."},{"key":"1067_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","volume":"18","author":"H Yamanaka","year":"2016","unstructured":"Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18:34. https:\/\/doi.org\/10.1186\/s13075-016-0932-2.","journal-title":"Arthritis Res Ther."},{"key":"1067_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ijid.2017.11.016","volume":"66","author":"HF Tseng","year":"2018","unstructured":"Tseng HF, Chi M, Hung P, Harpaz R, Schmid DS, LaRussa P, et al. Family history of zoster and risk of developing herpes zoster. Int J Infect Dis. 2018;66:99\u2013106. https:\/\/doi.org\/10.1016\/j.ijid.2017.11.016.","journal-title":"Int J Infect Dis."},{"key":"1067_CR24","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/s0002-9149(00)00766-9","volume":"85","author":"AL Klatsky","year":"2000","unstructured":"Klatsky AL, Armstrong MA, Poggi J. Risk of pulmonary embolism and\/or deep venous thrombosis in Asian-Americans. Am J Cardiol. 2000;85:1334\u20137. https:\/\/doi.org\/10.1016\/s0002-9149(00)00766-9.","journal-title":"Am J Cardiol."},{"key":"1067_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-01036-w","author":"PG Conaghan","year":"2021","unstructured":"Conaghan PG, Mysler E, Tanaka Y, Da Silva-Tillmann B, Shaw T, Liu J, et al. Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program. Drug Saf. 2021. https:\/\/doi.org\/10.1007\/s40264-020-01036-w.","journal-title":"Drug Saf."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01067-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01067-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01067-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:45:54Z","timestamp":1628617554000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01067-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01067-x","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"30 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by AbbVie, who contributed to the study design; data collection, analysis and interpretation; and writing, reviewing, and approval of the final version.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kunihiro Yamaoka has received speakers bureau fees from AbbVie GK, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Mitsubishi Tanabe Pharma Corporation, Pfizer Japan Inc., and Takeda Pharmaceutical Co. Ltd. Yoshiya Tanaka has received speaking fees and\/or honoraria from AbbVie, Asahi-Kasei Pharma Corporation, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd, Eisai Co. Ltd, Eli Lilly Japan KK, Gilead, GlaxoSmithKline KK, Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation, Novartis, Pfizer Japan Inc., Sanofi KK, and YL Biologics; and research grants from AbbVie, Chugai Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd, Eisai Co. Ltd, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co. Ltd, and UCB. Hideto Kameda has received consulting fees, speaking fees, and\/or honoraria from AbbVie GK, Asahi-Kasei Pharma Corporation, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd, Eli Lilly Japan KK, Gilead, Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation, Novartis, Pfizer Japan Inc., Sanofi KK, and UCB Japan; and research grants from AbbVie GK, Asahi-Kasei Pharma Corporation, Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd, Eisai Co. Ltd, Mitsubishi Tanabe Pharma Corporation, and Novartis. Nasser Khan, Nobuhito Sasaki, Yanna Song, and Ying Zhang are employees of AbbVie and may own stocks or stock options. Masayoshi Harigai has received grants from AbbVie Japan Co. Ltd, Bristol-Myers Squibb KK, Chugai Pharmaceutical Co. Ltd, Eisai Co. Ltd, Mitsubishi Tanabe Pharma Co., Santen Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd, and Teijin Pharma, Ltd; and personal fees from AbbVie Japan Co. Ltd, Astellas Pharma Inc., Bristol-Myers Squibb KK, Chugai Pharmaceutical Co. Ltd, Eisai Co. Ltd, Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Santen Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd, and Teijin Pharma, Ltd. Tsutomu Takeuchi has received grants from AbbVie GK, Asahi-Kasei Pharma Corporation, Astellas Pharma Inc., AYUMI Pharmaceutical Corporation, Chugai Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd, Eisai Co. Ltd, Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co. Ltd, Novartis Pharma KK, Pfizer Japan Inc., and Takeda Pharmaceutical Co. Ltd; and personal fees from AbbVie GK, Astellas Pharma Inc., AstraZeneca KK, Bristol-Myers Squibb KK, Chugai Pharmaceutical Co. Ltd, Daiichi Sankyo Co. Ltd, Eisai Co. Ltd, Eli Lilly Japan KK, GlaxoSmithKline KK, Janssen Pharmaceutical KK, Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co. Ltd, Novartis Pharma KK, Pfizer Japan Inc., Sanofi KK, Teijin Pharma Ltd, Taiho Pharmaceutical Co. Ltd, Taisho Pharmaceutical Co. Ltd, Takeda Pharmaceutical Co. Ltd, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All studies were conducted according to the International Conference on Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines, applicable regulations and guidelines governing clinical study conduct, and the Declaration of Helsinki. Study-related documents were reviewed and approved by independent Ethics Committees and Institutional Review Boards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan and execution of a Data Sharing Agreement. Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study concept\/design, data acquisition, analysis, and interpretation, as well as writing and critical review of the manuscript. All authors provided final approval of the submitted version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}